WS #8493
The dominant signal in this window is the escalation of US-Iran ceasefire optimism, with Bloomberg reporting stocks holding at record highs on US-Iran deal optimism, while OilPrice.com reports a massive selloff in crude futures on ceasefire talks. This is corroborated by Polymarket trades on Strait of Hormuz normalization and US-Iran peace deals. Chevron's CEO stating the firm will bypass the Strait of Hormuz and not pay transit tolls adds a counter-signal, suggesting infrastructure adaptation that could dampen the bullish oil thesis. Separately, Blue Origin's New Glenn rocket exploded during a test, casting doubt on NASA's Moon plans and Amazon's Kuiper satellite timeline, which is a negative for space/defense sentiment. Ukraine struck Russian oil infrastructure (Volgograd refinery, Yaroslavl pumping station), escalating energy supply risks. Dell Technologies surged 37% on strong Q1 results and raised guidance, with BofA raising its price target to $500, driving sympathy moves in HPE and broader tech. NetApp and UiPath also reported strong results. Bitcoin slid to April lows, diverging from record-chasing US equities, with ETF outflows reaching a record nine-day streak ($2.8B). The aluminum squeeze deepens as spreads tighten and inventories drop, a second-order effect from Middle East conflict. Replimune surged 40% on FDA approval path agreement for its melanoma treatment. Gap shares fell after cutting FY26 sales guidance. The US-Iran ceasefire narrative is ESCALATING from prior chatter to concrete market impact, with oil prices reacting sharply.
Key developments
- US-Iran ceasefire optimism drives crude selloff, stocks at record highs
- Blue Origin New Glenn rocket explodes during test, delays NASA Moon plans and Amazon Kuiper
- Ukraine strikes Russian oil refinery in Volgograd and pumping station in Yaroslavl
- Dell Technologies surges 37% on strong Q1 results, raised FY27 guidance
- Bitcoin ETF outflows hit record nine-day streak of $2.8B, BTC slides to April lows
- Aluminum squeeze deepens as spreads tighten and inventories drop
- Replimune surges 40% on FDA approval path agreement for melanoma treatment
- Gap cuts FY26 sales guidance, shares fall after-hours